Reduction of Homologous Transfusions in Open-Heart Surgery

Abstract

Use of homologous blood is relatively frequent in cardiac surgery and represents a potential risk for sensitivity or infective contamination.

A prospective study on 744 patients (operated on before September, 1986, and considered as the control group) revealed that the incidence of posttransfusion hepatitis was 12.7% (mean overall blood loss was 1270±115 mL; bank-blood-transfused patients comprised 91.9% of the group; and bank-blood-transfused units averaged 8.6/patient).

From September, 1986, to December, 1990, 924 patients underwent elective open-heart operations. Autotransfusion only was used in group A (400 patients). Aprotinin was added to autotransfusion in group B (192 patients). Aprotinin only was used in group C (332 patients). The bank blood requirement was reduced drastically in all groups. In group A, mean blood loss was 870±85 mL, and transfusions were required in 29.7% of patients with a mean bank blood unit/patient of 2.6 ± 1.8. In group B, mean blood loss was 425 ± 55 mL, and transfusions were required in 11.5% of patients, with a mean bank blood unit/patient of 1.8 ± 1.3. In group C, mean blood loss was 405 ± 45 mL, 31.9% of patients had bank blood transfusion, and mean bank blood unit/patient was 2.1±1.2.

The incidence of posttransfusion hepatitis was 4.2% in group A, whereas no infective complications were found in the other groups.

The basal mean hematocrit value in groups A and B was 42.1±2.7% and 41.4±2.0%, respectively, and preoperatively, after a blood withdrawal of 3 units, was, respectively, 34.8±1.9% and 33.8±1.1%. In group C the mean preoperative hematocrit value was 41.7 ±2.2%. Mean hematocrit values at discharge were similar in all three groups, ranging around 30%.

Platelet count dropped in group A after surgery (-41%) and increased in the postoperative period, never reaching the basal value. Patients receiving aprotinin (groups B and C) presented a lower postoperative platelet decrease (respectively -28.6% and - 26.1 %), with a discharge value lower than basal.

Autologous blood collection and aprotinin administration proved to be a well-tolerated and uncomplicated method. This represented the most important and effective blood-saving procedure in cardiac surgery, minimizing the bank blood requirement and minimizing or even eliminating posttransfusion complications.

Get full access to this article

View all access options for this article.

References

Armitage P. : Statistical Methods in Medical Research. Oxford : Blackwell Scientific Publications, 1985.

Silver H. : Banked and fresh autologous blood in cardiopulmonary bypass surgery . Transfusion 15:600-603, 1975.

Tector AJ , Gabriel RP , Mateicka WE , et al: Reduction of blood usage in open heart surgery. Chest 70:454-457, 1976.

Kaplan JA , Cannarella C. , Jones EL , et al: Autologous blood transfusion during cardiac surgery. A re-evaluation of three methods. J Thorac Cardiovasc Surg 74:4-10, 1977.

Cosgrove DM : Blood conservation during myocardial revascularization. Ann Thorac Surg 28:184, 1979.

Britton LW , Eastlund DT , Dzubian SW , et al: Predonated autologous blood use in elective cardiac surgery . Ann Thorac Surg 47:529-532, 1989.

Owings DB , Kruskall MS , Thurer LR , et al: Autologous blood donations prior to elective cardiac surgery . JAMA 262:1963-1968, 1989 .

Alajmo F. , Calamai G. , Perna AM , et al: High-dose aprotinin: Hemostatic effects in open heart operations . Ann Thorac Surg 48:536-539, 1989.

Royston D. , Bidstrup BP : Reduction in post operative blood loss in patients having open heart reoperations using high dose aprotinin (Trasylol). Anesthesiology 67:A23, 1987.

10.

Royston D. , Bidstrup BP , Taylor KM , et al: Effect of aprotinin on need of blood transfusion after repeat open heart surgery. Lancet 1:1289-1291, 1987.

11.

Bidstrup BP , Royston D. , Sapsford RN , et al: Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 97:364-372, 1989.

12.

Dietrich W. , Barankay A. , Dilthey G. , et al: Reduction of homologous blood requirement in cardiac surgery by intraoperative aprotinin application—clinical experience in 152 cardiac surgical patients. Thorac Cardiovasc Surg 37:92-98, 1989.

13.

Fraedrich G. , Weber C. , Bernard C. , et al: Reduction of blood transfusion requirement in open heart surgery by administration of high doses of aprotinin—preliminary results. Thorac Cardiovasc Surg 37:89-91, 1989.

14.

van Oeveren W. , Harder MP , Roozendaal KJ , et al: Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 99:788-797, 1990.

15.

Angelini GD , Cooper GJ , Lamarra M. , et al: Unorthodox use of aprotinin to control life-threatening bleeding after cardiopulmonary bypass . Lancet 335:799-800, 1990.

16.

Covino E. , Pepino P. , Iorio D. , et al: Low dose aprotinin as blood saver in open heart surgery. Eur J Cardiothorac Surg 5:414-418, 1991.

17.

Blundell J. : Experiments on the transfusion of blood by the syringe. Medica Chir Trans 9:56-58, 1918.

18.

Duncan J. : On re-infusion of blood in primary and other amputation. Br Med J 1:192-194, 1886.

19.

Wilson JD : Autotransfusion: Historical review and preliminary report on a new method . Mayo Clin Proc 43:23-26, 1968.

20.

Silvergleid AJ : Preoperative autologous donation: What have we learned? Transfusion 31:99-102, 1991.

21.

Tice DA , Reed GE , Clauss RH , et al: Hemorrhage due to fibrinolysis occurring with open heart operations . J Thorac Cardiovasc Surg 46:673-679, 1963.

22.

Sirchia G. , Parravicini A. , Giovannetti AM , et al: La trasfusione degli anni '90: scienza ed organizzazione. Milano: Centro trasfusionale Ospedale Maggiore Policlinico di Milano ed., 1988.

23.

Alter HJ , Purcell RH , Feinstone SM , et al: Non-A and non-B hepatitis. A review and interim report of an ongoing prospective study. In: Viral Hepatitis, ed. by Vyas GN , Cohen S. Philadelphia: The Franklin Institute Press, 1978.

24.

Koziol DE , Holland PV , Alling DW , et al: Antibody to hepatitis B core antigen as a paradoxal marker for non-A, non-B hepatitis agents in donated blood. Ann Intern Med 104:488-495, 1986.